Print(PDF/67KB) Mar. 22, 2017 Corporate

Sumitomo Dainippon Pharma Announces New Chief Executive Officer at Boston Biomedical, Inc. and Establishment of Global Head of Oncology

Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; President: Masayo Tada) today announced the following change of chief executive officer at its U.S. consolidated subsidiary Boston Biomedical, Inc. and establishment of Global Head of Oncology, effective April 24,2017.

I. Change of Chief Executive Officer at Boston Biomedical, Inc. (effective April 24, 2017)

(1) Reason for change

Retirement of current Chief Executive Officer Chiang J. Li at the expiration of his term of office and appointment of new Chief Executive Officer

(2) Details of appointment changes

Name New Position Current position
Patricia S. Andrews CEO, Boston Biomedical, Inc. Executive Vice President and COO , Boston Biomedical Pharma, Inc. *1
Chiang J. Li *2 President, CEO and CMO, Boston Biomedical, Inc.

* 1 As announced on December 21, 2016, Boston Biomedical Pharma, Inc. will merge with Boston Biomedical, Inc., effective April 1, 2017 (surviving company: Boston Biomedical, Inc.). * 2 Chiang J. Li will retire from the position of Head of Global Oncology for Sumitomo Dainippon Pharma Group as well as from Boston Biomedical, Inc., and will be appointed Senior Special Oncology Advisor of Sumitomo Dainippon Pharma, Co. Ltd., effective May 1, where he will provide advice on the instructions of the president of Sumitomo Dainippon Pharma.

II. Establishment of Global Head of Oncology (effective April 24, 2017)

With the retirement of Chiang J. Li, the new position of Global Head of Oncology will be established, effective April 24, and Kazuo Koshiya will be appointed to this position. Effective on the same date, Yasushi Matsuki will assume the position of Senior Director of DSP Cancer Institute.
Global Head of Oncology will take the lead in overall oncology business of Sumitomo Dainippon Group. Sumitomo Dainippon Pharma Group positions oncology as one of its focus therapeutic areas. Under the leadership of Global Head of Oncology, Sumitomo Dainippon Pharma (DSP Cancer Institute, Oncology Clinical Development Unit), Boston Biomedical, Inc. and Tolero Pharmaceuticals, Inc. (Headquarters: Lehi, UT, U.S., CEO: David J. Bearss) will collaborate on R&D with the aims of continuously creating innovative compounds and accelerating filings and approvals of development pipeline in order for oncology products to contribute to company performance as early as possible.

The positions of Kazuo Koshiya and Yasushi Matsuki as of April 24 will be as follows.

Name Position as of April 24 Current position
Senior Executive Officer
Boston Biomedical, Inc.;
Global Oncology Office; Oncology
Clinical Development Unit; Oncology
Strategy Unit; DSP Cancer Institute;
Global Head of Oncology
Senior Executive Officer
Boston Biomedical Pharma, Inc.;
Global Oncology Office; Oncology
Clinical Development Unit; Oncology
Strategy Unit; Head of Global
Oncology Office
Senior Director, Global Oncology
Senior Director, DSP Cancer Institute
Senior Director, Global Oncology

(Reference:Oncology pipeline)

The products in Sumitomo Dainippon Pharma Group's oncology pipeline that are being developed with a view to early regulatory filing are the cancer stemness inhibitors napabucasin and amcasertib, the cyclin-dependent kinase 9 inhibitor alvocidib, and the WT1 cancer peptide vaccine DSP-7888.

As already announced, napabucasin is currently in multiple phase 3 studies. We are aiming at regulatory filings for the indications of gastric cancer and gastroesophageal junction adenocarcinoma (combination therapy) in the U.S.A. and Japan in fiscal year 2018. Regarding alvocidib, a phase 2 study is being conducted in patients who have tested positive for acute myeloid leukemia (AML) biomarkers in the U.S.A. and the group aims to file an application for approval of this indication in fiscal year 2018 at the earliest.

Inquiries from the Press